Opioid-induced hyperalgesia

Why can taking a strong painkiller for months leave a person more sensitive to pain than before?

A drug that blunts pain is taken for months, and the pain comes back. The obvious reading is that the drug has stopped working — the familiar story of tolerance, where the same dose buys less and the answer is more dose. This collection has a piece on exactly that, and everything in it holds.

But a second possibility looks identical from outside and is the opposite underneath: that the drug is not merely failing to suppress pain but is producing pain of its own. If so, the two situations demand opposite responses while presenting the same complaint. So the question worth chasing is not "why does the effect fade" — it is "how could you ever tell these apart?"

Start by being precise about the two claims, because they are geometrically different. Tolerance shifts the dose-response curve to the right: the maximum achievable effect is intact, it simply takes more drug to reach a given point. Hyperalgesia moves the baseline — the pain the person would report with no drug at all is now worse than before they started. One is a change in the drug's grip; the other, a change in the person's pain system.

That difference has an immediate consequence, and it is the whole diagnostic key. Add drug to a tolerant system and you climb back up the curve, so pain improves, at least for a while. Add drug to a hyperalgesic system and you feed the very process generating the pain, so it does not improve and may worsen. The direction the pain moves when the dose goes up separates them. Nothing else about the two presentations does.

Now ask what mechanism could produce a raised baseline, because a claim like that needs a body to live in. Opioid receptor signalling does not act on an inert system; it is opposed by pro-nociceptive machinery that ramps up under sustained exposure. Several strands are documented in animal work: glutamate signalling at NMDA receptors driving central sensitisation in the spinal cord; upregulation of spinal dynorphin; facilitation descending from the rostral ventromedial medulla, where cells switch from damping incoming signals to amplifying them; and glial activation. Rodents on sustained morphine, or repeated remifentanil, show lowered thermal and mechanical thresholds — they hurt sooner, to stimuli that are not the original injury.

Note the relationship to tolerance rather than treating them as rivals. The piece on tolerance describes this in passing: with opioids the cell not only turns down its own gain but upregulates the pathway the drug suppresses. Push that far enough and the opposing pathway does not merely cancel the drug — it exceeds the ground it started from. On this reading the two are one adaptation measured against different reference points: against the drug's effect it reads as tolerance, against the original baseline as hyperalgesia. That is probably too tidy, since the two can be dissociated experimentally, but it is the right place to start.

Now the honesty this topic demands. The animal evidence is strong. The human evidence is much weaker, and the question is genuinely contested. Volunteer studies using quantitative sensory testing after remifentanil infusions do show reduced pain thresholds afterwards — about as clean a human demonstration as exists. But in patients on long-term opioids for chronic pain, three other explanations produce the same picture and are hard to exclude: the disease has progressed; tolerance alone is at work; or what looks like increased sensitivity is withdrawal between doses, since the unopposed counter-adaptation is itself hyperalgesic and resolves the moment the next dose lands. Nor can such studies randomise who ends up on opioids. Anyone claiming a confident prevalence figure here is going beyond the evidence, and I am declining to give one.

What would refute the account. Two observations, either of which would leave it with nothing. First, if controlled volunteer studies — no disease to progress, no chronic-pain population to confound — showed pain thresholds unchanged by opioid exposure once withdrawal had passed, the core claim fails. Second, if increased sensitivity never extended beyond the territory of the original pain, disease progression would explain everything and no drug-produced state need be invoked. The spread of sensitivity into regions the original injury never touched carries the most weight, precisely because no account of the disease can reach there.

Four things need separating, because more than one can run at once.

Tolerance: same dose, less effect; the underlying pain unchanged. More drug helps, temporarily.

Between-dose withdrawal: the counter-adaptation showing through as the drug level falls. It tracks the dosing interval and resolves on the next dose — which is the clue.

Disease progression: pain in the same place, of the same character, following the anatomy that caused it.

Hyperalgesia: pain spreading beyond the original site, often diffuse and hard to localise, in which stimuli that should not hurt — light touch, a blood pressure cuff — do. It does not improve with more drug.

A misconception worth correcting: hyperalgesia is not a sign that someone is exaggerating, drug-seeking, or "addicted". It is a pharmacological consequence in a nervous system that adapted as nervous systems do, and it occurs in people with no craving and no loss of control whatever. Confusing it with addiction is a category error with real costs for the person carrying it.

It is also distinct from central sensitisation in general, which can arise from injury and inflammation with no drug involved; the claim here is only that sustained opioid exposure is one thing capable of driving it.

Finally, a boundary this piece will not cross. Nothing above tells anyone what to do with a medication. Whether a dose should be reduced, held, rotated, or left alone depends on the person and their disease — and reducing an opioid unsupervised has its own hazards, including a withdrawal period during which pain typically worsens first. That decision belongs to a clinician who can examine the person.